PIK3CA and ovarian carcinoma: This present study investigated the novel combination of PI3K/mTOR and ERK inhibitors against ovarian cancer and provides evidence of the potential efficacy of the combination of BEZ235 and SCH772984 against ovarian cancer with a robust synergistic interaction seen in OV-90 2D monolayers, 3D aggregates and 3D spheroids as well as OVCAR8 monolayers and OVCAR5 aggregates.